Specify a stock or a cryptocurrency in the search bar to get a summary
Aerovate Therapeutics Inc
AVTEAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Address: 930 Winter Street, Waltham, MA, United States, 02451
Analytics
WallStreet Target Price
2.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures AVTE
Dividend Analytics AVTE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AVTE
Stock Valuation AVTE
Financials AVTE
Results | 2019 | Dynamics |